EC
EC8.F CONMED Corporation
- Market cap
- EUR 1.35B
- P/E
- 21.7x
- P/B
- 1.45x
- ROE
- 7.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EC8.F undervalued?
Graham numberEC8.F trades 18.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CONMED Corporation fundamental analysis
No fundamental analysis for CONMED Corporation yet.
CONMED Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, flui…
Full company profileCONMED Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CONMED Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 764M | 796M | 860M | 955M | 862M | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B | 1.33B |
| Gross Profit | 408M | 431M | 469M | 525M | 460M | 568M | 571M | 676M | 733M | 750M | 760M |
| Operating Income | 37.7M | 46.9M | 71.3M | 79.1M | 46.0M | 110M | 70.1M | 121M | 200M | 103M | 132M |
| EBITDA | - | 105M | 133M | 146M | 118M | 109M | -42.0M | 192M | 272M | 176M | 212M |
| Net Income | 14.7M | 55.5M | 40.9M | 28.6M | 9.52M | 62.5M | -80.6M | 64.5M | 132M | 47.1M | 75.6M |
| EPS | - | 1.98 | 1.45 | 1.01 | 0.33 | 2.13 | -2.64 | 2.10 | 4.29 | 1.52 | 2.53 |
| Balance Sheet | |||||||||||
| Total Assets | 1.33B | 1.36B | 1.37B | 1.78B | 1.75B | 1.77B | 2.30B | 2.30B | 2.31B | 2.33B | 2.30B |
| Total Liabilities | 748M | 727M | 707M | 1.06B | 1.04B | 981M | 1.55B | 1.47B | 1.34B | 1.29B | 1.24B |
| Shareholders' Equity | 581M | 631M | 662M | 710M | 709M | 785M | 746M | 834M | 963M | 1.03B | 1.06B |
| Cash & Short-term Investments | 27.4M | 32.6M | 17.5M | 25.9M | 27.4M | 20.8M | 28.9M | 24.3M | 24.5M | 40.8M | 48.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 39.9M | 65.6M | 74.7M | 95.1M | 64.5M | 112M | 33.4M | 57.4M | 167M | 171M | 133M |
| Capital Expenditure | 14.8M | 12.8M | 16.5M | 20.1M | 13.0M | 14.9M | 21.8M | 19.9M | 13.1M | 19.8M | 11.3M |
| Free Cash Flow | - | 52.7M | 58.2M | 75.1M | 51.5M | 96.9M | 11.6M | 37.5M | 154M | 151M | 122M |
| Ratios | |||||||||||
| ROE | 2.5% | 8.8% | 6.2% | 4.0% | 1.3% | 8.0% | -10.8% | 7.7% | 13.8% | 4.6% | 7.1% |
| ROA | 1.1% | 4.1% | 3.0% | 1.6% | 0.5% | 3.5% | -3.5% | 2.8% | 5.7% | 2.0% | 3.3% |
| Net Profit Margin | 1.9% | 7.0% | 4.8% | 3.0% | 1.1% | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% | 5.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CONMED Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 52.6%
- Ex-dividend date
- Sep 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 24.7M | 0.80 | 52.6% |
| 2024 | USD 24.7M | 0.80 | 18.6% |
| 2023 | USD 24.4M | 0.80 | 37.9% |
| 2022 | USD 24.0M | 0.79 | - |
| 2021 | USD 23.3M | 0.79 | 37.2% |
| 2020 | USD 22.8M | 0.79 | 239.8% |
| 2019 | USD 22.6M | 0.80 | 79.0% |
| 2018 | USD 22.4M | 0.80 | 54.9% |
| 2017 | USD 22.3M | 0.80 | 40.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CONMED Corporation
- Insiders 0.44%
- Institutions 99.56%
- Public & others 0.00%
- Shares outstanding 29.8M
- Free float 29.5M
CONMED Corporation company profile
- Company name
- CONMED Corporation
- Ticker
- EC8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,900
- Fiscal year end
- December
- Address
- 11311 Concept Boulevard, Largo, FL, United States, 33773
- Phone
- 727 392 6464
- Website
- conmed.com
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solutions comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures; and products to treat diseases of dilation, hemostasis, biliary, stricture management, and infection prevention, as well as ECG electrodes, EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
CONMED Corporation management
3- Mr. Patrick J. BeyerPresident, CEO & Director · born 1966
- Ms. Hollie K. FoustExecutive VP, General Counsel & Corporate Secretary · born 1975
- Mr. Peter K. ShagoryExecutive Vice President of Strategy & Corporate Development · born 1969